Showing results (471-480 of 492) with videos related to

Sort By:
Pageof 50
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|January 16, 2013
Smoking and 2-month culture conversion during anti-tuberculosis treatmentE L Maciel, A P Brioschi, R L Peres, et al.
Tuberculosis (Edinburgh, Scotland)|May 30, 2015
Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosisA Jayakumar, E Vittinghoff, M R Segal, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 30, 2012
Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatmentD Lamunu, K N Chapman, P Nsubuga, et al.
American Journal of Respiratory and Critical Care Medicine|July 3, 1999
Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapyL E Desjardin, M D Perkins, K Wolski, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 2, 2001
Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activationZ Toossi, J L Johnson, R A Kanost, et al.
The Journal of Infectious Diseases|May 24, 2001
Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosisH Mayanja-Kizza, J L Johnson, C S Hirsch, et al.
American Journal of Respiratory and Critical Care Medicine|April 14, 2000
Predicting the outcome of therapy for pulmonary tuberculosisR S Wallis, M D Perkins, M Phillips, et al.
The Journal of Infectious Diseases|November 7, 1998
Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatmentR S Wallis, M Perkins, M Phillips, et al.
The Journal of Infectious Diseases|April 8, 2000
Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research CollaborationJ L Johnson, R M Kamya, A Okwera, et al.
Clinical Pharmacology and Therapeutics|January 27, 2017
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trialsR M Savic, M Weiner, W R MacKenzie, et al.
Pageof 50